MedTrace Logo

To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers

NCT02706925 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2020-01-02

Study results available
· View outcomes & findings →

Summary

To investigate safety, tolerability and pharmacokinetics, following single doses of BI 443651

Conditions

  • Healthy

Interventions

DRUG

BI 443651

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-22
Primary Completion
2016-06-12
Completion
2016-06-13

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02706925 on ClinicalTrials.gov